ironmatt Research GrantS
Pediatric brain tumor research is a long and expensive process.
It can take years to complete a single study. And it can take well over 15 years and $5 billion to turn a laboratory discovery into a new drug that impacts a patients’ life.
A scientist operating a research lab spends $50,000 to $500,000 each year on equipment and salaries, plus $20,000 or more a year for materials used in the lab. They need anywhere from $300 to $500 for cancer cells to use in just one experiment and as much as $800 on a single bottle of specialized solution.
This investment in time and resources is significant, but the potential impact is incalculable. Research is the only way we will discover and deliver cures to children with pediatric brain tumors — and IronMatt is dedicated to supporting research into this terrible disease.
As of 2023, IronMatt has granted over $6 million, funding 75 research projects at institutions across the U.S. and Canada.
Our Rigorous Review Process
At IronMatt, we use a rigorous peer review process to select research grants. Peer review is a grant review process used by many organizations, including the National Institute of Health, to determine which research grants will be funded.
Through this process, we strive to fund the very best research — funding projects that have the potential to advance the field and impact patients’ lives as rapidly as possible.
Grant applicants are encouraged to submit pre-clinical and clinical grant requests for pediatric brain cancer. Grants are evaluated via our peer review process by the Medical Advisory Committee (MAC).
Apply to the Matthew Larson Research Grant today, and join the fight against childhood brain cancer.
How to Apply
To be considered for the 2024 research grant, applicants must first submit a letter of intent by November 19, 2023.
Our MAC will review your letter of intent, and if selected, you will be invited to submit a formal application.
2023 IronMatt Grant Award Winners
Each winner of the 2023 IronMatt Research Grant received a one-year grant of $75,000.
Dr. Jamie Anastas
Baylor College of Medicine, Houston, TX.
Therapeutic Targeting of Serotonin and Cyclin Dependent Kinase Signaling in DMG
Dr. Peter Madsen
Children’s Hospital of Philadelphia, Philadelphia, PA.
Novel CAR T Cell Therapy for Atypical Teratoid Rhabdoid Tumor
Dr. Antony Michealraj
Children’s Hospital of Pittsburgh Foundation, Pittsburgh, PA.
Dr. Antony Michealraj.
Targeting Metabolic and Therapeutic Vulnerabilities of Lethal Pediatric Ependymomas
Dr. Jun Qi
Dana-Farber Cancer Institute, Boston, MA.
Development of SMARCA4 Inhibitor with BBB Penetration for Brain Cancers
Dr. Winson Ho
The Regents of the University of California, Los Angeles, CA.
Protein Phosphatase 2A (PP2A) Inhibition to Enhance cGAS-STING Mediated Tumor
Dr. Rintaro Hashizume
The University of Alabama at Birmingham, Birmingham, AL.
Immunogenicity in Medulloblastoma, Intranasal Delivery of PDGFRA-Targeted Nanotherapeutics for Treating Pediatric High-Grade Glioma
Previous Grant Recipients
A pediatric brain tumor diagnosis is not a journey anyone should travel alone.
Together, we can free families from financial stress and fight childhood brain cancer.
Together, we are strong. We are fearless. We are IronMatt.
IronMatt Grants in the News
IronMatt Grant Recipient Finds Promising Medulloblastoma Therapy Target
Current treatments have improved the survival rate of children with medulloblastoma, but children who fall under the high-risk category are prone to having the tumor spread to other parts of
IronMatt Acknowledged for Funding Groundbreaking Results in Clinical Trials
A phase 1 trial of a treatment for DIPG, or diffuse intrinsic pontine glioma, looks promising. DIPG is an aggressive type of childhood cancer that forms in the brainstem. With
IronMatt Acknowledged in Neuro-Oncology Article
One of IronMatts’ 2015 grant recipients, Dr. Javad Nazarian, was published in Neuro-Oncology’s September 2022 issue. You can read the full article here. This study defined the molecular mechanism and
